tailieunhanh - Osimertinib in advanced EGFRT790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

AURA study reported 61% objective response rate and progression-free survival of months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to describe the experience with osimertinib in Spain. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN